Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Diagnostic & Testing Substances Manufacturers

Jun 29, 2021 08:30 am ET
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark amended the protocol to include study participants receiving immunotherapy and added the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) as an additional site under the supervision of Dr Philippe Joubert. The amended protocol is intended to test the hypothesis that downregulation of SSAT1 activity as reflected by a reduced plasma concentration of acetylamantadine, will occur earlier than can be detected by other diagnostic testing methods used to determine the efficacy of chemotherapy combined or not to immunotherapy in patients with a diagnosis of stage III lung cancer. This amendment approval from Health Canada will facilitate the study and permit achieving the required sample size in a timely manner. Patient recruitment is anticipated to commence later in the 3rd quarter.
Jun 01, 2021 08:30 am ET
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform. The total sponsored research grant is about $825,000 and a major portion of the funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+) and Spark grant from the Canadian Cancer Society (CCS, grant # 707073), the Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR, grant # 0590008438), and Brain Canada Foundation.
May 31, 2021 08:30 am ET
BioMark Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announces that it has changed its auditors from Manning Elliott LLP ("Former Auditor") to PricewaterhouseCoopers LLP ("Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors of the Company appointed the Successor Auditor effective as of the same date, until the next Annual General Meeting of the Company.
Apr 29, 2021 08:30 am ET
Biomark to Open a Diagnostic Laboratory in Quebec
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment.
Apr 21, 2021 08:30 am ET
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company's private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty maturity date of April 16, 2021. The gross proceeds to the company from the exercise of the warrants are expected to be approximately $400,000.00.
Mar 16, 2021 08:30 am ET
Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation, evaluated the full proposal for its relevance to funding opportunities in the prevention and early detection of cancer. The funding application is entitled "A novel rapid, liquid biopsy early-stage lung cancer diagnostic test". The grant was for $150,000.
Mar 02, 2021 08:30 am ET
BioMark Grants Options
Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has granted 2,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two years from the date of grant. All other terms and conditions of options are in accordance with the terms of the Company's Stock Option Plan.
Feb 16, 2021 08:30 am ET
BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. ("Phytronix") to advance the development of BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology. While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec City to accelerate commercialization of its assays, the Quebec-based Phytronix will bring its experience in high-throughput analysis, automated sample preparation and assay development to this collaboration.
Feb 08, 2021 08:30 am ET
BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that the article "Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer - a Pilot Study" has been published in the peer-reviewed journal Future Science OA.
Jan 11, 2021 08:30 am ET
Alfred Berkeley Joins BioMark's Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark") is glad to announce Alfred Berkeley as a new member of the BioMark's Advisory team, as he will be providing strategic and financial advice to help expand the company's commercialization effort in the U.S.
Dec 07, 2020 08:30 am ET
BioMark Retains Questrade, Inc. to Provide Market-Making Services
Vancouver, British Columbia--(Newsfile Corp. - December 7, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that it has retained Questrade, Inc. ("Questrade") to provide market-making services in accordance with CSE guidelines.
Sep 23, 2020 08:30 am ET
BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark's SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).
Sep 16, 2020 08:30 am ET
BioMark Appoints Dr. Jean-Francois Haince as Strategic Advisor to Guide Its Expansion into Quebec
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team.
Sep 14, 2020 08:30 am ET
BioMark Team Invited for Full Application for Sparks Grant Competition
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation, evaluated the abstracts for their relevance to funding opportunities in the prevention and early detection of cancer.
Aug 27, 2020 08:30 am ET
BioMark Team Secures Health Canada Letter of No Objection for Its Glioblastoma Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2020) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA.
Aug 13, 2020 08:30 am ET
BioMark Diagnostics Expands Research Development in Quebec
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship.
Jul 21, 2020 08:30 am ET
Jul 16, 2020 08:30 am ET
BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark"
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2020) -  BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark". The term "BioMark" was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations.
Jun 23, 2020 08:30 am ET
BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off patent drug for a new application.
Jun 18, 2020 08:30 am ET
BioMark Receives European Patent for Cancer Diagnostic
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the company has been granted a patent titled "A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE." The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase activity. The patent will cover a novel approach to diagnosing and monitoring various forms of cancer.
Jun 16, 2020 08:30 am ET
Bio Stream Diagnostics Inc. Selected for CDL Rapid Response Innovation Program
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab's (CDL) recent dedicated Recovery program. CDL Recovery is designed to help turn science and research work into scalable products and services to address the consequences of the COVID-19 pandemic, in terms of both its effects on public health and the economy. CDL Recovery is focused on the full stack of information-based solutions in an attempt to accelerate the world's recovery from the COVID-19 crisis.
Jun 11, 2020 05:37 pm ET
BioMark Diagnostics Inc. Clarifies Prior Disclosure
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated by the Company on June 10, 2020 with respect to the formation of Bio Stream Diagnostics Inc., a new company, focused on providing low-cost COVID-19 detection in less-than-30 seconds. Leveraging Raman spectroscopy and the power of machine learning, the Bio Stream platform is anticipated to provide low-cost, accurate results in coronavirus screening. The clarification was requested by IIROC and offers expanded disclosure that is addressed below.
Jun 10, 2020 08:30 am ET
BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for '30-Second' COVID-19 Screening
Rapid COVID-19 testing will use machine learning and advanced Raman spectroscopy to provide low-cost, accurate results
May 29, 2020 04:30 pm ET
BioMark Announces Filing of Amended and Restated MD&A for the Three and Nine Months Ended December 31, 2019
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.
Mar 24, 2020 06:30 am ET
BioMark's Liquid Biopsy Assay Levering Metabolomics Demonstrates Strong Performance for Early Lung Cancer Detection
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC PINK: BMKDF) ("BioMark") is pleased to announce that the article "A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection" has been published in the peer-reviewed journal Cancers, validating BioMark's technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test.
Mar 16, 2020 08:30 am ET
BioMark Diagnostics Advanced Raman Spectrometer Could Potentially Serve as Complementary Detection Tool for COVID -19 / Coronavirus
Originally created as part of the company's cancer ultra sensitive and small molecule specific detection system, the device has potential to identity many infectious diseases
Feb 04, 2020 04:02 am ET
BioMark's Market Update Report
Vancouver, British Columbia - TheNewswire – February 4th, 2020  – BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) (FSE:20B) (OTC:BMKDF) (CNSX:BUX.CN) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020.
Jan 21, 2020 06:01 am ET
BioMark's Scientific Advisor Named Dean of Schulich School of Medicine and Dentistry
Vancouver, British Columbia  - TheNewswire – January 21, 2020 – BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo  for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020.
Dec 31, 2019 02:12 am ET
BioMark Announces Appointment of Scientific and Medical Advisors, Grant of Stock Options and Changes in Board of Directors
Vancouver, British Columbia  - TheNewswire - December 31, 2019 - BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce addition of distinguished experts to its scientific and medical advisory team. This new group of advisors will further strengthen our team and support our upcoming commercialization initiatives. Announcements relating to the appointment to each adviser will be made through appropriate news release.
Dec 19, 2019 06:12 am ET
BioMark Diagnostics Reviews 2019 and Outlines Plans for 2020
Vancouver, British Columbia - TheNewswire – December 19th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to provide 2019 round up and our outlook for 2020. Below are key highlights.
Dec 16, 2019 06:12 am ET
BioMark Closes the Over-Subscribed Private Placement Offering
Vancouver, British Columbia - TheNewswire - December 16th, 2019 - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce that further to its press release of November 21st, 2019, it has closed the non-brokered private placement for gross proceeds of $669,347.00 wherein BioMark issued 2,231,157 units at a price of $ 0.30 per unit.
Dec 11, 2019 06:12 am ET
Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics
Vancouver, British Columbia - TheNewswire – December 11th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) (CNSX:BUX.CN) (FSE: 20B) (OTC:BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to be featured in the official magazine of the Canadian Trade Commissioner Service (TCS) Life Sciences Special Edition. Please find below the link for the article on BioMark.
Nov 21, 2019 07:11 am ET
Correction: BioMark Announces Private Placement
Vancouver, British Columbia – TheNewswire - November 21st, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000.
Nov 21, 2019 06:11 am ET
BioMark Announces Private Placement
Vancouver, British Columbia - TheNewswire – November 21st, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 5,000,000 Units at a price of $0.30 to raise gross proceeds of up to $500,000.
Nov 19, 2019 06:11 am ET
BioMark Signs Letter of Intent for Licensing Relationship for Clinical Validation and Development
Vancouver, British Columbia – TheNewswire - November 19th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce that it has signed a Letter of Intent (LOI) with a Chinese company named GuangDong Longhu (Longhu) related to an anticipated licensing relationship. BioMark has been in discussions with Longhu and its management group for the past 12 months. BioMark management team travelled to Longhu’s facilities to explore the technical, scientific, financial and medical infrastructure that Longhu can provide to BioMark. BioMark obtained due dilige
Aug 27, 2019 07:08 am ET
New Scientific Publication Further Supports BioMark's Assay
Vancouver, British Columbia - TheNewswire – August 27th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTCMKTS:BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal Future Science OA.
Aug 19, 2019 07:08 am ET
BioMark's Liquid Biopsy Scientific Paper to Be Featured as Cover on Cancers Upcoming Issue
Vancouver, British Columbia – TheNewswire - (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTC:BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers.
Aug 13, 2019 07:08 am ET
New Advances in Liquid Biopsy to Increase BioMark's Assay Performance
Vancouver, British Columbia – TheNewswire - August 13th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CNSX:BUX.CN) (FSE:20B) (OTCMKTS:BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers.
Jun 26, 2019 07:06 am ET
The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics
Vancouver, British Columbia - TheNewswire - June 26, 2019 - BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that BioMark and the University of Maryland School of Medicine (UMSOM) have entered into a collaboration related to the discovery and validation of biomarkers using a combinatorial technology approach. This collaboration follows several productive meetings between BioMark and UMSOM clinicians and lab service specialists as well as employees in UMSOM’s offices of technology transfer, research affairs, and research and development.
Jun 18, 2019 07:06 am ET
BioMark announces Debt Settlement
Vancouver, British Columbia / TheNewswire / June 18, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that it has arranged a voluntary debt to share settlement (the "Debt Settlement") with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company by such directors and officers (and for which amounts had accrued as reflected in the Company’s financial statements but which had not been paid).
May 30, 2019 07:05 am ET
BioMark Announces New Patent Granted in United States
Vancouver, British Columbia / TheNewswire / May 30th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States.
May 01, 2019 07:05 am ET
Revision on Total Funding Secured by BioMark and its Team of Collaborators on CHRP Application
Vancouver, British Columbia / TheNewswire / May 1st, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) would like to correct its  news release dated on  April 17TH. 2019 announcing the approval of  the application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity.  The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Resea
Apr 17, 2019 07:04 am ET
BioMark and its Team of Collaborators Secure CHRP Funding
 Vancouver, British Columbia / TheNewswire / April 17, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity, has been approved. The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaborat
Apr 16, 2019 07:04 am ET
BioMark Closes the Private Placement Offering
April 16th, 2019 / TheNewswire / Vancouver, British Columbia - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of April 9th, 2019, it has closed the non-brokered private placement for gross proceeds of $200,000.00 wherein BioMark issued 2,000,000 units at a price of $ 0.10 per unit.
Apr 09, 2019 07:04 am ET
BioMark Announces Private Placement
Vancouver, British Columbia / TheNewswire / April 9th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 2,000,000 Units at a price of $0.10 to raise gross proceeds of up to $200,000.
Apr 03, 2019 07:04 am ET
BioMark's Abstract Accepted for 2019 ASCO Online Publication
Vancouver, British Columbia / TheNewswire / April 3, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled "Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity".
Mar 14, 2019 07:03 am ET
BioMark Contributes Additional Scientific Publication
Vancouver, British Columbia / TheNewswire /  BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA.
Mar 12, 2019 07:03 am ET
BioMark Announces New Patent Granted in China
Vancouver, British Columbia / TheNewswire / March 12, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been granted in China on February 15, 2019.
Nov 05, 2018 06:11 am ET
Dr. Myron Weisfedlt Joins BioMark's Scientific Advisory Team
Vancouver, British Columbia / TheNewswire / November 5th, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team.
Oct 04, 2018 07:10 am ET
BioMark Closes Final Tranche of Private Placement Offering
October 4th, 2018 / TheNewswire / Vancouver, British Columbia - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 units at a price of $ 0.10 per unit.
Oct 02, 2018 07:10 am ET
Dr. Sandeep Singhal Joins BioMark Scientific Advisory Team
October 2, 2018 / TheNewswire / Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team.
Sep 26, 2018 07:09 am ET
BioMark Contributes in Scientific Publication
Vancouver, British Columbia / TheNewswire / September 26, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA.
Sep 19, 2018 07:09 am ET
Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team
Vancouver, British Columbia / TheNewswire / September 19th, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team.
Apr 25, 2018 07:04 am ET
BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making
Vancouver, British Columbia / TheNewswire / April 25, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Osmar Zaïane of the University of Alberta’s Department of Computing Science and his team to assess and employ machine intelligence to augment BioMark’s breakthrough biological molecular diagnostics for lung cancer that leverages the power of metabolomics.
Feb 27, 2018 07:02 am ET
BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant
Vancouver, British Columbia / TheNewswire / (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of  Pharmacology and Therapeutics  at the University of Manitoba, to fabricate new nanomaterial and focus on evaluation of these new nanomaterial for knocking down SSAT1 expression in various cells .The up regulation of  SSAT enzyme  has been clinically demonstrated by BioMark and others to be highly e
Feb 21, 2018 07:02 am ET
BIOMARK's Health Canada Submission Update
Vancouver, British Columbia / TheNewswire / February 21, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities.
Jul 05, 2016 08:00 am ET
BioMark Completes Data Collection and Submits Data for Analysis Prior to Health Canada Submission
BioMark Diagnostics Inc. ("BioMark" or the "Company") CSE:BUX)(FRANKFURT: 20B)(OTCQB: BMKDF), a leader in next-generation cancer diagnostics using metabolites, is pleased to announce that its designated analytical service provider Biopharmaceutical Research Inc (BRI) has completed the raw data collection for the 200 patient trial using an internal standard developed for BioMark that meets Health Canada and US FDA standards.
Jul 05, 2016 07:58 am ET
BioMark Completes Data Collection and Submits Data for Analysis Prior to Health Canada Submission
BioMark Diagnostics Inc. ("BioMark" or the "Company") CSE:BUX)(FRANKFURT:20B)(OTCQB:BMKDF), a leader in next-generation cancer diagnostics using metabolites, is pleased to announce that its designated analytical service provider Biopharmaceutical...
Jun 24, 2016 08:00 am ET
BioMark Closes Second Tranche of Private Placement Offering
VANCOUVER, British Columbia, June 24, 2016 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) is pleased to announce that further to its press release dated June 20, 2016, it has closed the second tranche of a non-brokered private placement for gross proceeds of $163,615 wherein BioMark issued 1,090,767 units at a price of $0.15 per unit....
Jun 20, 2016 08:00 am ET
BioMark Engages Stockhouse.com Deal Room with Private Placement
VANCOUVER, British Columbia, June 20, 2016 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) is pleased to announce it has engaged Stockhouse Deal Room in connection with closing the second tranche of its current private placement....